Interleukin-17 inhibitors for the treatment of ankylosing spondylitis
Abstract: Tumor necrosis factor inhibitor (TNFi) has been applied in the treatment of ankylosing spondylitis (AS) for many years but still with an unmed need due to inefficacy or intolerance. Current treatment guideline recommended the use of IL-17 inhibitors over a second TNFi in patients with primary nonresponse to the first TNFi. We herein review the present available IL-17 inhibitors including secukinumab (SEC), ixekizumab (IXE), brodalumab and bimekizumab (BKZ) in clinical trials of AS. Therapeutic response and safe profile have been discussed in detail for each drug. Overall, IL-17 inhibitors were proved to be alternatives for biologic disease-modifying anti-rheumatic drugs (bDMARDs) in AS, which might be safer for tuberculosis while candida infection should be monitored in long term treatment.
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
Interleukin-17 inhibitors for the treatment of ankylosing spondylitis ; volume:1 ; number:1 ; year:2020 ; pages:25-29 ; extent:5
Rheumatology and immunology research ; 1, Heft 1 (2020), 25-29 (gesamt 5)
- Urheber
-
Huang, Jin-Xian
Zhang, Li-Jun
Wei, James Cheng-Chung
- DOI
-
10.2478/rir-2020-0004
- URN
-
urn:nbn:de:101:1-2023030113045307208637
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:49 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Huang, Jin-Xian
- Zhang, Li-Jun
- Wei, James Cheng-Chung
Ähnliche Objekte (12)
Comparative Pharmacoeconomic Effectiveness of Interleukin-17 Inhibitors for the Treatment of Ankylosing Spondylitis
Erratum to: Comparative Pharmacoeconomic Effectiveness of Interleukin-17 Inhibitors for the Treatment of Ankylosing Spondylitis
Surgical treatment of ankylosing spondylitis deformity
Andersson lesion in ankylosing spondylitis
Network Meta-Analysis and Cost Per Responder of Tumor Necrosis Factor-α and Interleukin Inhibitors in the Treatment of Active Ankylosing Spondylitis
Treatment of ankylosing spondylitis with TNFα inhibitors does not affect serum levels of tryptophan metabolites
Interleukin-37 is increased in ankylosing spondylitis patients and associated with disease activity
Secukinumab: A Review in Ankylosing Spondylitis
Scoring radiographic progression in ankylosing spondylitis: should we use the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS) or the Radiographic Ankylosing Spondylitis Spinal Score (RASSS)?
Interleukin-35 promotes Breg expansion and interleukin-10 production in CD19+ B cells in patients with ankylosing spondylitis
ANKHvariants associated with ankylosing spondylitis: gender differences
Atherosclerosis in Egyptian patients with ankylosing spondylitis
Comparative Pharmacoeconomic Effectiveness of Interleukin-17 Inhibitors for the Treatment of Ankylosing Spondylitis
Erratum to: Comparative Pharmacoeconomic Effectiveness of Interleukin-17 Inhibitors for the Treatment of Ankylosing Spondylitis
Surgical treatment of ankylosing spondylitis deformity
Andersson lesion in ankylosing spondylitis
Network Meta-Analysis and Cost Per Responder of Tumor Necrosis Factor-α and Interleukin Inhibitors in the Treatment of Active Ankylosing Spondylitis
Treatment of ankylosing spondylitis with TNFα inhibitors does not affect serum levels of tryptophan metabolites
Interleukin-37 is increased in ankylosing spondylitis patients and associated with disease activity
Secukinumab: A Review in Ankylosing Spondylitis
Scoring radiographic progression in ankylosing spondylitis: should we use the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS) or the Radiographic Ankylosing Spondylitis Spinal Score (RASSS)?
Interleukin-35 promotes Breg expansion and interleukin-10 production in CD19+ B cells in patients with ankylosing spondylitis
ANKHvariants associated with ankylosing spondylitis: gender differences
Atherosclerosis in Egyptian patients with ankylosing spondylitis
Comparative Pharmacoeconomic Effectiveness of Interleukin-17 Inhibitors for the Treatment of Ankylosing Spondylitis
Erratum to: Comparative Pharmacoeconomic Effectiveness of Interleukin-17 Inhibitors for the Treatment of Ankylosing Spondylitis
Surgical treatment of ankylosing spondylitis deformity
Andersson lesion in ankylosing spondylitis
Network Meta-Analysis and Cost Per Responder of Tumor Necrosis Factor-α and Interleukin Inhibitors in the Treatment of Active Ankylosing Spondylitis
Treatment of ankylosing spondylitis with TNFα inhibitors does not affect serum levels of tryptophan metabolites
Interleukin-37 is increased in ankylosing spondylitis patients and associated with disease activity
Secukinumab: A Review in Ankylosing Spondylitis
Scoring radiographic progression in ankylosing spondylitis: should we use the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS) or the Radiographic Ankylosing Spondylitis Spinal Score (RASSS)?
Interleukin-35 promotes Breg expansion and interleukin-10 production in CD19+ B cells in patients with ankylosing spondylitis
ANKHvariants associated with ankylosing spondylitis: gender differences